» Articles » PMID: 39232721

Eslicarbazepine Induces Apoptosis and Cell Cycle Arrest in C6 Glioma Cells in Vitro and Suppresses Tumor Growth in an Intracranial Rat Model

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2024 Sep 4
PMID 39232721
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Glioblastoma multiforme (GBM) is the most malignant brain tumor, with a poor prognosis and life expectancy of 14-16 months after diagnosis. The standard treatment for GBM consists of surgery, radiotherapy, and chemotherapy with temozolomide. Most patients become resistant to treatment after some time, and the tumor recurs. Therefore, there is a need for new drugs to manage GBM. Eslicarbazepine (ESL) is a well-known antiepileptic drug belonging to the dibenzazepine group with anticancer potentials. In this study, for the first time, we evaluated the potential effects of ESL on C6 cell growth, both in vitro and in vivo, and examined its molecular effects.

Methods: To determine the effect of ESL on the c6 cell line, cell viability, proliferation, and migration were evaluated by MTT assay, colony formation, and wound healing assay. Also, apoptosis and cell cycle were examined by flow cytometry, qRT-PCR, and western blotting. In addition, an intracranial model in Wistar rats was used to investigate the effect of ESL in vivo, and the tumor size was measured using both Caliper and MRI.

Results: The obtained results are extremely consistent and highly encouraging. C6 cell viability, proliferation, and migration were significantly suppressed in ESL-treated C6 cells (p < 0.001), as determined by cell-based assays. ESL treatment led to significant enhancement of apoptosis (p < 0.01), as determined by flow cytometry, and upregulation of genes involved in cell apoptosis, such as the Bax/Bcl2 ratio at RNA (p < 0.05) and protein levels (5.37-fold). Flow cytometric analysis of ESL-treated cells revealed G2/M phase cell cycle arrest. ESL-treated cells demonstrated 2.49-fold upregulation of p21 alongside, 0.22-fold downregulation of cyclin B1, and 0.34-fold downregulation of cyclin-dependent kinase-1 at the protein level. Administration of ESL (30 mg/kg) to male rats bearing C6 intracranial tumors also suppressed the tumor volume and weight (p < 0.01).

Conclusions: Based on these novel findings, ESL has the potential for further experimental and clinical studies in glioblastoma.

References
1.
Lee J, Hall R . The Impact of Gliomas on Cognition and Capacity. J Am Acad Psychiatry Law. 2019; 47(3):350-359. DOI: 10.29158/JAAPL.003841-19. View

2.
Song Y, Zhong M, Cai F . Oxcarbazepine causes neurocyte apoptosis and developing brain damage by triggering Bax/Bcl-2 signaling pathway mediated caspase 3 activation in neonatal rats. Eur Rev Med Pharmacol Sci. 2018; 22(1):250-261. DOI: 10.26355/eurrev_201801_14126. View

3.
Scheibel R, Meyers C, Levin V . Cognitive dysfunction following surgery for intracerebral glioma: influence of histopathology, lesion location, and treatment. J Neurooncol. 1996; 30(1):61-9. DOI: 10.1007/BF00177444. View

4.
Bouckaert C, Germonpre C, Verhoeven J, Chong S, Jacquin L, Mairet-Coello G . Development of a Rat Model for Glioma-Related Epilepsy. Int J Mol Sci. 2020; 21(19). PMC: 7582710. DOI: 10.3390/ijms21196999. View

5.
Mukand J, Blackinton D, Crincoli M, Lee J, Santos B . Incidence of neurologic deficits and rehabilitation of patients with brain tumors. Am J Phys Med Rehabil. 2001; 80(5):346-50. DOI: 10.1097/00002060-200105000-00005. View